Naptumomab estafenatox is under clinical development by NeoTX Therapeutics and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase II drugs for Metastatic Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naptumomab estafenatox’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Naptumomab estafenatox overview
ABR-217620 (anyara, naptumomab estafenatox) is under development for the treatment of advanced or metastatic solid tumors including pancreatic adenocarcinoma, ovarian cancer, cervical squamous cell carcinoma, prostate cancer, ER+/HER2- or triple negative breast cancer, non-small cell lung cancer, mesothelioma, renal cell carcinoma, bladder cancer, urothelial cancer, head and neck carcinoma, melanoma, hepatocellular carcinoma, endometrial cancer, metastatic colorectal cancer, adenocarcinoma of the pancreas and gastroesophageal cancer. The drug candidate is administered intravenous bolus route. The drug candidate targets 5T4 molecule expressed on the surface of tumor cells. The drug candidate is a second generation tumor targeted superantigen and is selectively retained in tumor tissue. ABR-217620 is a recombinant fusion protein genetically fused anti-5T4 Fab moiety and engineered superantigen variant SEA/E-120.
ABR-217620 (anyara, naptumomab estafenatox) was under development for the treatment of renal cell cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer.
NeoTX Therapeutics overview
NeoTX Therapeutics, formerly Predictive Therapeutics, is a clinical-stage biopharmaceutical company which focuses on the development of immuno-oncology therapies. The company utilizes its proprietary Tumor Targeted Superantigen (TTS) platform to develop targeted anticancer immunotherapies. Its pipeline product candidates include NTX-352, NTX-353, NTX-354 which are in Phase I clinical development targeted to cover tumor cells with molecules which direct the patient’s immune system against the tumor. NeoTx Therapeutics lead TTS molecule, naptumomab estafenatox (NAP) is in clinical development for non-small cell lung cancer and other solid tumors. The company partners with other pharmaceutical and clinical trial organizations for the development of products and technologies. NeoTX Therapeutics is headquartered in Rehovot, Israel.
For a complete picture of Naptumomab estafenatox’s drug-specific PTSR and LoA scores, buy the report here.